7494 J. Am. Chem. Soc., Vol. 120, No. 30, 1998
GroVes, et al.
erative disorders,25-38 heart diseases,
39,40
chronic inflammation
ischemia-reperfusion
Mn(III)TMPyP and its amphiphilic analogues requires the
presence of biological antioxidants, and the concentrations of
these antioxidants might be low under conditions of oxidative
stress, when the levels of prooxidants and antioxidants are not
41-44
45-47
and autoimmune diseases,
injury,
cancer,
1
,48-51
52
and septic shock. This large and rapidly expand-
-
ing body of evidence on the role of ONOO in a wide variety
of human diseases has naturally led to a search for drugs that
can intercept this powerful oxidant.
5
7,58
-
in balance.
Thus, it is highly desirable to develop ONOO
decomposition catalysts that function even in the absence
biological antioxidants.
-
We have recently shown that ONOO reacts rapidly and
5
9
stoichiometrically with the water-soluble synthetic manganese
porphyrin 5,10,15,20-tetrakis(N-methyl-4′-pyridyl)porphinato-
manganese(III) [Mn(III)TMPyP] to generate oxomanganese
Mn(III)TMPyP catalyzed the rapid reduction
of ONOO in the presence of biological antioxidants, such as
ascorbate, glutathione, and Trolox (a water-soluble analogue
of R-tocopherol). In addition to this “peroxynitrite reductase”
activity, Mn(III)TMPyP has been shown to possess significant
activity for the simultaneous oxidation of superoxide (O2 ) and
reduction of ONOO . Furthermore, amphiphilic analogues
of Mn(III)TMPyP have been prepared which proved to be
Stern et al. have shown that 5,10,15,20-tetrakis(N-methyl-
4′-pyridyl)porphinatoiron(III) [Fe(III)TMPyP] and 5,10,15,20-
tetrakis(2,4,6-trimethyl-3,5-sulfonatophenyl)porphinatoiron-
(III) [Fe(III)TMPS] display profound activity in biological
17,53
intermediates.
-
-
models of ONOO related disease states and have been
-
investigated as therapeutic agents for diseases in which ONOO
has been implicated.
54
59-62
These iron porphyrins were proposed
to possess catalytic “peroxynitrite isomerase” activity, converting
-•
-
-
ONOO to NO3 . However, a consensus has not yet been
-
55
-
reached on the mechanism of ONOO decomposition catalyzed
by these iron porphyrins.
-
effective ONOO decomposition catalysts in liposomal as-
Herein we elaborate on the reactions of Fe(III)TMPyP with
semblies.5 The fast catalytic turnover of both the water-soluble
6
-
ONOO . Significantly, both Fe(III)TMPyP and oxoFe(IV)-
-
TMPyP have been found to react with ONOO under typical
(
25) Lipton, S. A.; Chol, T.-B.; Pan, Z.-H.; Lei, S. Z.; Chen, H.-S.;
Sucher, N. J.; Loscalzo, J.; Singel, D. J.; Stamler, J. S. Nature 1993, 364,
26-631.
26) Good, P. F.; Werner, P.; Hsu, A.; Olanow, C. W.; Perl, D. P. Am.
catalytic conditions, which accounts for the significant difference
in activity between iron and manganese porphyrins toward
peroxynitrite. In addition, we have studied the SOD activity
of Fe(III)TMPyP. As we have recently described for Mn(III)-
6
(
J. Pathol. 1996, 149, 21-28.
(
(
27) Matthews, R. T.; Beal, M. F. Brain Res. 1996, 718, 181-184.
28) Bonfoco, E.; Krainc, D.; Ankarcrona, M.; Nicotera, P.; Lipton, S.
A. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7162-7166.
29) Beckman, J. S.; Carson, M.; Smith, C. D.; Koppenol, W. H. Nature
993, 364, 584.
5
5
TMPyP, the SOD activity of Fe(III)TMPyP may be ac-
-
•
-
companied by a O2 -coupled ONOO reductase pathway. The
(
-•
-
simultaneous and redox-coupled removal of O2 and ONOO
1
by Fe(III)TMPyP may explain the remarkable biological activity
of this and other iron porphyrins.
(
(
30) Rosen, D. R.; et al.; Brown, R. H. Nature 1993, 352, 59-62.
31) Wiedau-Pazos, M.; Goto, J. J.; Rabizadeh, S.; Gralla, E. B.; Roe, J.
A.; Lee, M. K.; Valentine, J. S.; Bredesen, D. E. Science 1996, 271, 515-
18.
32) Deng, H. X.; Hentati, A.; Tainer, J. A.; Iqbal, Z.; Cayabyab, A.;
Hung, W. Y.; Getzoff, E. D.; Hu, P.; Herzfeldt, B.; Roos, R. P.; Warner,
C.; Deng, G.; Soriano, E.; Smyth, C.; Parge, H. E.; Ahmed, A.; Roses, A.
D.; Hallewell, R. A.; Pericak-Vance, M. A.; Siddique, T. Science 1993,
Results and Discussion
5
Elucidation of the mechanism of ONOO- isomerization
catalyzed by water-soluble iron porphyrins such as Fe(III)-
TMPyP and Fe(III)TMPS depends on the identification of the
reactive intermediates and on the development of an understand-
ing of the reaction kinetics. Peroxynitrite, the anion of
peroxynitrous acid (ONOOH), is expected to react as a typical
peroxide, and reactions of peroxides with iron porphyrins and
heme-dependent enzymes are known to produce reactive oxoiron
(
2
61, 1047-1051.
33) Crow, J. P.; Sampson, J. B.; Zhuang, Y. X.; Thompson, J. A.;
Beckman, J. S. J. Neurochem. 1997, 69, 1936-1944.
(
(
90.
34) Dawson, V. L.; Dawson, T. M. J. Chem. Neuroanat. 1996, 10, 179-
1
(
(
35) Szabo, C. Free Radical Biol. Med. 1996, 21, 855-869.
36) Zhang, J.; Dawson, V. L.; Dawson, T. M.; Snyder, S. H. Science
63-68
intermediates.
For example, compound I of the peroxidase
1
994, 263, 687-689.
37) Adamson, D. C.; Wildermann, B.; Sasaki, M.; Glass, J. D.;
McArthur, J. C.; Christov, V. I.; Dawson, T. M.; Dawson, V. L. Science
enzymes has been described as an oxoFe(IV) porphyrin cation
radical, while compound II has been described as an oxoFe-
(
6
9-73
1
996, 274, 1917-1921.
38) Lipton, S. A.; Rosenberg, P. A. New Engl. J. Med. 1994, 330, 613-
22.
39) White, C. R.; Brock, T. A.; Chang, L.; Crapo, J.; Briscoe, P.; Ku,
(IV) species.
An oxoFe(IV) porphyrin cation radical,
(
analogous to compound I of the peroxidases but with a thiolate
axial ligand, is believed to be the active intermediate in various
6
(
6
3
D.; Bradley, W. A.; Gianturco, S. H.; Gore, J.; Freeman, B. A.; Tarpey, M.
reactions catalyzed by the family of cytochrome P450
74
M. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 1044-1048.
enzymes. For iron porphyrin model systems, both the oxoFe-
(40) Shimojo, T.; Nishiwaka, T.; Ishiyama, S.; Ikeda, I.; Kasajima, T.;
(IV) porphyrin cation radical and the oxoFe(IV) species have
Marumo, F.; Hiroe, M. CardioVasc. Pathol. 1998, 7, 25-30.
7
5,76
been isolated and well-characterized.
The reaction of
(
41) Kaur, H.; Halliwell, B. FEBS Lett. 1994, 350, 9-12.
(42) Rachmilewitz, D.; Stamler, J. S.; Karmeli, F.; Mullins, M. E.; Singel,
(52) Szabo, C.; Salzman, A. L.; Ischiropoulos, H. FEBS Lett. 1995, 363,
235-238.
(53) Groves, J. T.; Marla, S. S. J. Am. Chem. Soc. 1995, 117, 9578-
9579.
(54) Lee, J.; Hunt, J. A.; Groves, J. T. Bioorg. Med. Chem. Lett. 1997,
7, 2913-2918.
(55) Lee, J.; Hunt, J. A.; Groves, J. T. J. Am. Chem. Soc. 1998, 120,
6053-61.
(56) Hunt, J. A.; Lee, J.; Groves, J. T. Chem. Biol. 1997, 4, 845-858.
(57) Scandalios, J. G. OxidatiVe Stress and the Molecular Biology of
Antioxidant Defenses; Cold Spring Harbor Laboratory Press: New York,
1997.
(58) Sies, H. OxidatiVe Stress; Academic Press: Orlando, FL, 1985.
(59) Stern, M. K.; Jensen, M. P.; Kramer, K. J. Am. Chem. Soc. 1996,
118, 8735-8736.
D. J.; Loscalzo, J.; Xavier, R. J.; Podolski, D. K. Gastroenterology 1993,
05, 1681-1688.
43) Seo, H. G.; Takata, I.; Nakamura, M.; Tatsumi, H.; Suzuki, K.; Fujii,
J.; Taniguchi, N. Arch. Biochem. Biophys. 1995, 324, 41-47.
44) Haddad, I. Y.; Pataki, G.; Hu, P.; Beckman, J. S.; Matalon, S. J.
Clin. InVest. 1994, 94, 2407-2413.
45) Mannick, E. E.; Bravo, L. E.; Zarama, G.; Realpe, J. L.; Zhang, X.
1
(
(
(
J.; Ruit, B.; Fontham, E. T. H.; Mera, R.; Miller, M. J. S.; Coprea, P. Cancer
Res. 1996, 56, 3238-3243.
(
46) Douki, T.; Cadet, J.; Ames, B. N. Chem. Res. Toxicol. 1996, 9,
3
-7.
(
(
(
47) Juedes, M. J.; Wogan, G. N. Mutation Res. 1996, 349, 51-61.
48) Chan, P. H. Stroke 1996, 27, 1124-1129.
49) Huang, Z.; Huang, P. L.; Panahian, N.; Dalkara, T.; Fishman, M.
C.; Moskowitz, M. A. Science 1994, 265, 1883-1885.
50) Ma, X. L.; Lopez, B. L.; Liu, G. L.; Christopher, T. A.; Ischirop-
oulos, H. CardioVasc. Res. 1997, 36, 1195-204.
51) Alayash, A. I.; Ryan, B. A. B.; Cashon, R. E. Arch. Biochem.
Biophys. 1998, 349, 65-73.
(60) Stern, M. K.; Salvemini, D. PCT Int. Appl. WO95/31197, 1995.
(61) Salvemini, D.; Wang, Z.-Q.; Bourdon, D. M.; Stern, M. K.; Currie,
M. G.; Manning, P. T. Eur. J. Pharmacol. 1996, 303, 217-220.
(62) Salvemini, D.; Wang, Z. Q.; Stern, M. K.; Currie, M. G.; Misko,
T. P. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2659-2663.
(
(